Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
about
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibIbrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaThe clinical implications of gene mutations in chronic lymphocytic leukaemiaChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaThe influence of subclonal resistance mutations on targeted cancer therapyPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsNew strategies in chronic lymphocytic leukemia: shifting treatment paradigmsTargeting cancer with kinase inhibitorsTargeted therapies in CLL: mechanisms of resistance and strategies for managementClinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyondClinical tumor sequencing: opportunities and challenges for precision cancer medicineNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewCIViC databaseAcquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaSecond-generation inhibitors of Bruton tyrosine kinaseIdentifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentSecondary mutations as mediators of resistance to targeted therapy in leukemiaGenomic and epigenomic heterogeneity in chronic lymphocytic leukemiaComprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation SequencingThe European Hematology Association Roadmap for European Hematology Research: a consensus documentCovalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia.Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsUnification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosisDistinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
P2860
Q26744277-B774709F-0122-4D55-A46E-487CA910624EQ26749010-4E9AED30-B3C1-4AD1-8CCB-3C05A04E82C2Q26749214-36765CD6-F28B-47BF-8D91-CC87691073DCQ26764833-5C7D59BC-5C2E-4B7D-BF4C-D91C1609C94CQ26775506-28BE87DC-98DA-41F2-9D9C-E03F44AD7684Q26781693-B833AA38-C30B-42F1-9A2E-AD0FD03A33D9Q26782633-45A295FC-0B72-46B9-AD0E-2E18FCB53009Q26783430-9B5DA1DE-0BD1-4578-ABDE-4EB2E94C4F77Q26795594-EF3861AF-D6C4-4FCA-9BF2-FFB8702351A1Q26828496-03C94A38-45BA-4DA5-BD46-CA7FCDCA7BD5Q26865765-A7158EFF-523F-4927-906B-7922B9465BE0Q27002528-3E4CB6D9-406C-4153-B9CC-282156BCEECBQ27027493-DF7C77BB-71DC-492C-9A23-F55A2F42ACECQ27027942-18FC9822-3490-4035-A2F8-C3318C4F17B0Q27304386-1C1CA316-6B2E-4D84-8D91-F27AC97B760BQ27612411-F054BFEC-EE34-47FB-8F37-5399A8B97A1BQ27853162-D9DD9391-15F4-4D0C-992E-0395D910329EQ27853190-B4A0404B-CC90-4999-8F25-B7F54DE79664Q28075504-657EFCA0-7102-4F4E-8949-F62568739D5DQ28075683-5E7A3328-6574-4E64-A70E-D6464BEECCAAQ28076118-C6DA1B34-73C6-49E3-B854-F7237A415367Q28077136-41C9EE4C-889F-48B5-B366-C5B54CDA1DE6Q28081162-99218B85-4E55-4ABA-9B3A-8165E76B7F81Q28082086-CD845D7D-489F-4A8B-BE11-E9FF918579F9Q28087213-B0036AC1-BF16-43F0-9444-C1FF51718FD8Q28087672-11A084AA-6615-4D4F-8914-9058CC16A9FCQ28547976-A5B2AEB5-1BFA-4C8E-9A60-72CD30E763D1Q28830861-56D076C8-1993-441A-B173-3D317F36EA7DQ29248430-1F80DE01-A0F3-42D4-B76D-F383BD384275Q30243968-46601909-B4F0-4DF2-B755-8214DDE93698Q30248407-0729F0B5-0A57-4B21-A23A-D4BB18D8738FQ30252869-507D9C42-59DB-4D6E-A3B4-712028CC6110Q33419580-4F9529EB-7B34-4FE0-AF8E-C1D106187F32Q33420278-CB7E0056-6502-491F-BA8A-22A4BF4F6F0BQ33442484-7F1F0974-2BBA-48B3-9946-A2579757917FQ33566747-7667D9B5-09D4-4D0B-A380-3EDB34C1261AQ33587128-6E96A9B2-E450-45AF-B01A-3296BA8DA0EEQ33774517-8EDA930C-2F2D-4280-BE20-4FB6C44DC884Q33785941-C2EF9A8F-5C38-44F3-8FD3-3825F1A516C0Q33851726-FF90D1C8-9B08-4A70-9CEC-41B3FD7479B3
P2860
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@ast
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@en
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
@nl
type
label
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@ast
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@en
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
@nl
altLabel
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
@en
prefLabel
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@ast
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@en
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
@nl
P2093
P2860
P50
P3181
P356
P1476
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
@en
P2093
Amy J Johnson
Amy S Ruppert
Arletta Lozanski
Ayse Selen Yilmaz
Betty Y Chang
Danelle F James
Daniel Hsieh-Hsin Li
Gerard Lozanski
Hatice Gulcin Ozer
Jennifer A Woyach
P2860
P304
P3181
P356
10.1056/NEJMOA1400029
P407
P577
2014-06-12T00:00:00Z